Jupiter Life Line Hospitals (JLHL) Q4 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 25/26 earnings summary
18 May, 2026Executive summary
FY 2026 marked milestones with early commissioning of Dombivli hospital ahead of schedule and on budget, acquisition of BKC land for a 400-bed hospital, and expansion to four hospitals in MMR, two in Pune, and one in Indore.
The expansion strategy focuses on asset-heavy, owned infrastructure in densely populated urban areas, aiming for long-term operational stability and leadership in Western India.
Approved audited consolidated and standalone financial results for the year and quarter ended March 31, 2026, with unmodified audit opinions from statutory auditors.
Interim dividend of 10% per equity share (Rs. 1 per share) declared for FY 2025-26, record date May 22, 2026.
Board approved a 1:5 stock split, reducing face value from Rs. 10 to Rs. 2 per share, subject to shareholder approval.
Financial highlights
FY 2026 total income reached INR 1,499.8 crore, up 15.2% year-over-year; EBITDA was INR 343.3 crore, up 14.4%, with a margin of 22.9%.
PAT for the year was INR 194.2 crore; Q4 revenue was INR 387.8 crore, up 15.1%, with EBITDA at INR 89.2 crore (23% margin) and PAT at INR 50.2 crore, up 11.5%.
Consolidated net profit for FY 2025-26 was Rs. 1,941.87 million, compared to Rs. 1,937.54 million last year.
ARPOB grew 11.7% to INR 67,700; ALOS was 3.87 days; bed occupancy for the three established hospitals was 61.2%.
Insurance revenues comprised 55.4% of the revenue mix.
Outlook and guidance
Dombivli hospital expected to reach EBITDA breakeven within two years of operation; insurance empanelment and accreditation processes underway, likely to complete in 6-12 months.
Pune South hospital on track to open in calendar year 2028; Mira Road project to begin excavation by year-end.
Thane hospital expansion pending final regulatory approvals, expected within the financial year.
Scaling bed capacity to 2,900 with new projects in Dombivli, Pune II, Mira-Bhayandar, and BKC, with phased commissioning to optimize capital deployment.
Stock split expected to enhance share liquidity and affordability for retail investors.
Latest events from Jupiter Life Line Hospitals
- Revenue and EBITDA increased, but PAT fell due to labor code; major hospital expansion underway.JLHL
Q3 25/2610 Apr 2026 - Q1 FY25 saw strong revenue, profit, digital accreditation, and capacity expansion.JLHL
Q1 24/253 Feb 2026 - Strong revenue and profit growth, with major expansion and capital investment underway.JLHL
Q2 24/253 Feb 2026 - Double-digit growth, strong ARPOB, and major expansions, with margin dilution from new hospitals.JLHL
Q2 25/2619 Dec 2025 - FY25 saw strong growth, a recommended dividend, and major expansion and restructuring.JLHL
Q4 24/2519 Dec 2025 - Q1 FY26 revenue and EBITDA rose, but PAT declined on higher costs; volumes and ARPOB up.JLHL
Q1 25/2619 Dec 2025 - Strong growth and expansion, with new hospitals funded by internal accruals and no new debt.JLHL
Q3 24/2519 Dec 2025